Medicaid: What to Watch in 2022
As 2022 kicks off, a number of issues are at play that could affect coverage and financing under Medicaid. This issue brief examines key issues to watch in Medicaid in the year ahead.
View the Latest: Build Back Better
Filter
-
-
Recent Efforts to Extend Medicaid Postpartum Coverage and What to Watch Looking Ahead
Policy WatchThis policy watch examines recent state and federal efforts to extend postpartum Medicaid coverage beyond 60 days.
-
How Could the Build Back Better Act Affect Uninsured Children?
Issue BriefThis brief examines characteristics of uninsured children in 2020 and discusses how current policy proposals, including outreach efforts, continuous eligibility requirements, and closing the coverage gap, could affect children’s health coverage. Recent efforts to expand coverage for adults could benefit children’s coverage, especially for children in non-expansion states if the coverage gap is filled as proposed by the Build Back Better Act (BBBA).
-
Build Back Better Would Reduce Disproportionate Share Hospital (DSH) Payments and Limit Uncompensated Care (UCC) Pools in Non-Expansion States
Policy WatchThe Build Back Better (BBB) Act proposes reducing disproportionate share hospital (DSH) allotments by 12.5% starting in federal fiscal year (FFY) 2023 and places limits on Medicaid uncompensated care (UCC) pools for non-expansion states. This policy watch explains what these payments are, what changes have been tied to the ACA, and examines potential implications of changes included in the BBB.
-
How Build Back Better Would Affect Drug Costs
FeatureProvisions in the bill that would lower prescription drug costs and reduce federal drug spending would take effect over the next several years, starting in 2023.
-
Medicaid Outpatient Prescription Drug Trends During the COVID-19 Pandemic
Issue BriefThis data note describes Medicaid prescription drug utilization and spending trends in calendar year 2020 compared to previous years to explore how the pandemic impacted Medicaid prescription drug utilization and spending.